Innoviva, Inc. Common Stock (INVA) is a publicly traded Healthcare sector company. As of May 21, 2026, INVA trades at $22.62 with a market cap of $1.61B and a P/E ratio of 3.12. INVA moved +2.35% today. Year to date, INVA is +11.03%; over the trailing twelve months it is +18.42%. Its 52-week range spans $16.52 to $25.15. Analyst consensus is buy with an average price target of $34.60. Rallies surfaces INVA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Innoviva’s Specialty Therapeutics Platform Hits $150M Revenue with 46% Growth: Innoviva has a $1.4 billion market cap, trading at a forward P/E of 10.83 after generating $400 million in annual revenue and $364 million in free cash flow from GSK royalties. Its Specialty Therapeutics platform now accounts for $150 million (40% of revenue) with 46% annual growth and high cash-flow leverage.
| Metric | Value |
|---|---|
| Price | $22.62 |
| Market Cap | $1.61B |
| P/E Ratio | 3.12 |
| EPS | $7.20 |
| Dividend Yield | 0.25% |
| 52-Week High | $25.15 |
| 52-Week Low | $16.52 |
| Volume | 24 |
| Avg Volume | 0 |
| Revenue (TTM) | $420.69M |
| Net Income | $504.34M |
| Gross Margin | 73.73% |
5 analysts cover INVA: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $34.60.